An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators  by Wynes, Murry W. et al.
631Journal of Thoracic Oncology ®  •  Volume 9, Number 5, May 2014
Introduction: The goal of personalized medicine is to treat patients 
with a therapy predicted to be efficacious based on the molecular 
characteristics of the tumor, thereby sparing the patient futile or toxic 
therapy. Anaplastic lymphoma kinase (ALK) inhibitors are effective 
against ALK-positive non–small-cell lung cancer (NSCLC) tumors, 
but to date the only approved companion diagnostic is a break-apart 
fluorescence in situ hybridization (FISH) assay. Immunohistochemistry 
(IHC) is a clinically applicable cost-effective test that is sensitive and 
specific for ALK protein expression. The purpose of this study was to 
assemble an international team of expert pathologists to evaluate a new 
automated standardized ALK IHC assay.
Methods: Archival NSCLC tumor specimens (n =103) previously 
tested for ALK rearrangement by FISH were provided by the inter-
national collaborators. These specimens were stained by IHC with 
the anti-ALK (D5F3) primary antibody combined with OptiView 
DAB IHC detection and OptiView amplification (Ventana Medical 
Systems, Inc., Tucson, AZ). Specimens were scored binarily as posi-
tive if strong granular cytoplasmic brown staining was present in 
tumor cells. IHC results were compared with the FISH results and 
interevaluator comparisons made.
Results: Overall for the 100 evaluable cases the ALK IHC assay was 
highly sensitive (90%), specific (95%), and accurate relative (93%) to 
the ALK FISH results. Similar results were observed using a majority 
score. IHC negativity was scored by seven of seven and six of seven 
evaluators on three and two FISH-positive cases, respectively. IHC 
positivity was scored on two FISH-negative cases by seven of seven 
readers. There was agreement among seven of seven and six of seven 
readers on 88% and 96% of the cases before review, respectively, and 
after review there was agreement among seven of seven and six of 
seven on 95% and 97% of the cases, respectively.
Conclusions: On the basis of expert evaluation the ALK IHC test 
is sensitive, specific, and accurate, and a majority score of multiple 
readers does not improve these results over an individual reader’s 
score. Excellent inter-reader agreement was observed. These data 
support the algorithmic use of ALK IHC in the evaluation of NSCLC.
Key Words: Non–small-cell lung cancer, Anaplastic lymphoma 
kinase, Immunohistochemistry, Fluorescence in situ hybridization, 
Companion diagnostics, Biomarkers, Crizotinib.
(J Thorac Oncol. 2014;9: 631–638)
Personalized medicine is at the forefront of lung cancer therapy with the goal to reduce the 1.4 million lung cancer 
deaths per year worldwide.1 The fundamental principal of per-
sonalized medicine is treating patients with a therapy predicted 
to be efficacious based on the molecular characteristics of the 
tumor, thereby sparing the patient any potential morbidity and 
mortality associated with ineffective therapy. Non–small-cell 
lung cancer (NSCLC) accounts for 85% of all lung cancer and 
the 5-year survival rate for NSCLC is only 16% because of late-
stage diagnosis2 and lack of effective systemic therapy. However, 
treatment for advanced disease has improved recently com-
mensurate with the identification of key oncogenic alternations 
driving tumorigenesis, such as activating somatic mutations or 
chromosomal rearrangements targetable with specific therapeu-
tics.3 Tumors harboring epidermal growth factor receptor muta-
tions are distinctly sensitive to epidermal growth factor receptor 
tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib,4–8 
whereas tumors containing anaplastic lymphoma kinase (ALK) 
gene rearrangements are sensitive to the ALK TKI crizotinib.9,10
ALK gene rearrangements were first discovered in NSCLC 
in 2007 by Soda et al.11 who identified that the 3′ end of ALK was 
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juxtaposed to the 5′ end of echinoderm  microtubule-associated 
protein-like 4 (EML4) gene attributable to an inversion within 
chromosome 2p. Although EML4 is the main fusion partner 
in NSCLC, the 2p21 break point (EML4) is variable and other 
chromosomal fusion partners have been reported, for example, 
kinesin family member 5B (KIF5B)–ALK, TRK-fused gene 
(TFG)–ALK, and kinesin light chain (KLC1)–ALK.12–15 The 
clinical significance of the numerous variant rearrangements 
has not been defined but is being investigated. The coiled-coil 
domains in the 5′ fusion partners promote dimerization and 
oligomerization, which leads to constitutive activation of the 
ALK kinase domain and downstream signaling pathways culmi-
nating in tumor cell proliferation, survival, and oncogenesis.13,16 
The incidence of ALK gene rearrangements is approximately 
3% to 4% in an unselected NSCLC population, which equates 
to roughly 40,000  ALK-positive patients/year worldwide.1,17
NSCLC tumors that contain ALK rearrangement are 
strikingly responsive to the ALK TKI crizotinib (PF-02341066, 
Xalkori; Pfizer, New York, NY), an adenosine triphosphate 
(ATP) competitive  small-molecule targeting the kinase domain 
in the ALK protein.18 An international multicenter phase I study 
initially demonstrated an objective response rate of 60.8% 
and a disease control rate of 84% among the 143 evaluable 
patients.9,10 The median duration of response was 49.1 weeks 
and the median progression-free survival (PFS) was 9.7 months 
for all, often heavily pretreated patients, but a PFS of 18.3 
months was observed for those receiving crizotinib as first-line 
therapy. The estimated overall survival at 6 and 12 months was 
87.9% and 74.8%, but these data are not fully mature. Interim 
results of an ongoing phase 2 study have shown an overall 
response rate of 53% and a median PFS of 8.5 months.19 Early 
results from a phase III study (PROFILE 1007) comparing che-
motherapy with crizotinib revealed an increase in PFS from a 
median of 3.0 months to 7.7 months and an overall response 
rate of 20% versus 65%.20 Numerous other phase III clinical 
trials are ongoing. Crizotinib received accelerated approval 
from the U.S. Food and Drug Administration (FDA) in 2011, 
but approval was contingent upon documentation of ALK posi-
tivity by an FDA-approved diagnostic test, and to date the only 
FDA-approved companion diagnostic is the fluorescence in situ 
hybridization (FISH) assay using the Vysis break-apart FISH 
probe kit (Abbott Molecular, Des Plaines, IL).21
Numerous studies indicate that immunohistochemistry 
(IHC), under the appropriate conditions, is sensitive and spe-
cific for determination of ALK protein expression22–28 and is 
a practical cost-effective alternative to the ALK FISH assay. 
In fact, there are even potential clinical benefits to ALK IHC 
over FISH, as demonstrated by significant clinical improve-
ment from crizotinib in ALK IHC-positive, FISH-negative 
patients.29,30 However, a standardized ALK IHC diagnostic test 
is required, as studies comparing IHC with FISH have used 
different ALK antibody clones, detection systems, antigen 
retrieval techniques, and scoring methods.
The purpose of this study was to convene an interna-
tional team of expert pathologists to evaluate the scoring of a 
new automated standardized ALK IHC assay kit that employs 
the antibody clone D5F3 (Ventana Medical Systems, Inc., 
[VMSI], Tucson, AZ), an ultrasensitive detection system 
(OptiView DAB, VMSI, Tucson, AZ), an interpretation guide 
and scoring method. The detection system used an extra 
amplification step that has been shown to improve visualiza-
tion of low-level ALK protein expression found in NSCLC 
compared with the same antibody clone and detection system 
without amplification.31 The ALK IHC positivity or negativity 
status from each expert reader was compared with the ALK 
FISH status and inter-reader comparisons were made.
PATIENTS AND METHODS
Patients
Archival NSCLC tumor specimens (n = 103) were pro-
vided by the international collaborators. The tumors provided 
were previously tested for ALK rearrangement by FISH assess-
ment and there were 48 FISH-positive cases, which consisted of 
five cytology blocks, eight biopsy samples, and 35 surgical resec-
tions, whereas there were 55 FISH-negative cases consisting of 
four cytology blocks, 14 biopsy samples, and 37 resections. The 
readers of the ALK IHC protein expression assay were blinded 
to the FISH status until after completion of the IHC scoring.
ALK Protein Expression
The specimens were sectioned at a thickness of 4 μM and 
stained by IHC within 3 weeks of the sectioning. ALK IHC stain-
ing was performed on a VENTANA BenchMark XT automated 
slide-processing system at Ventana Medical Systems, Inc.31,32 In 
brief, slides of NSCLC tumor were subjected to deparaffiniza-
tion using EZ Prep (VMSI) and extended Cell Conditioning 1. 
Tissue sections were then incubated with anti-ALK antibody 
(clone D5F3, VMSI) for 20 minutes. OptiView DAB IHC 
Detection Kit (VMSI) and OptiView Amplification Kit (VMSI) 
were used according to the manufacturer’s recommendations 
for the visualization of the bound primary antibody.31,32 Tissue 
slides were counterstained with Hematoxylin II (VMSI) and 
Bluing Reagent (VMSI). Slides were dehydrated and cleared 
before coverslipping with Tissu-Tek (Sakura Finetek Japan, 
Tokyo, Japan). Specimens were examined and evaluated by 
six pathologists and one pathology-trained clinical molecular 
biologist who assessed only the tumor region of the specimen 
by using a light microscope. Nontumor (alveolar macrophages, 
cells of neural origin, glandular epithelial staining, and cells 
within lymphocytic infiltrate), necrotic, degenerated, crushed, 
or clearly artifactual (edge, retraction, thermal) tissues were 
not scored. Specimens were scored positive if strong granular 
cytoplasmic brown staining in tumor cells (any percentage of 
positive tumor cells) was present. Homogenous staining of all 
the tumor cells was not required as long as there were regions 
with strong cytoplasmic staining. Cases were scored as negative 
if there was no or only weak cytoplasmic staining. Examples of 
positive and negative staining are shown in Figure 1. Before the 
interobserver study commenced the participants were presented 
with 10 cases, which were scored by the evaluators and then the 
plenum discussed the positive and negative criteria.
Statistical Analysis
For the calculation of all concordance estimates (IHC ver-
sus FISH), only cases recorded as evaluable were used. Individual 
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reader concordance was calculated using FISH as the reference 
group. The associated 95% confidence intervals were calculated 
using the score method. The overall concordance for all read-
ers when comparing IHC versus FISH is based on the weighted 
average of the individual reader concordance estimates; the 
95% confidence intervals were calculated using the percentile 
bootstrap method. The data were recorded in Microsoft Excel 
spreadsheets, and analyzed using SAS version 9.2.
RESULTS
Agreement between ALK protein 
expression and ALK break-apart by FISH
A total of 103 NSCLC specimens were blindly evalu-
ated by the panel and it was unanimously determined that 
three FISH-positive cases no longer contained any tumor tis-
sue and were therefore excluded from any further analysis. 
Table 1 shows the comparison between the ALK IHC results 
for each reader and the previously determined FISH results. 
The FISH status was not re-evaluated, and any differences in 
the number of cases for each reader reflects that reader’s dis-
cretion of evaluability of the IHC. The ALK IHC assay was 
highly sensitive, specific, and accurate relative to the ALK 
FISH results. Overall sensitivity, specificity, and accuracy 
were 90%, 95%, and 93%, respectively, with the ranges being 
87% to 91%, 94% to 96%, and 91–94%. After scoring the dis-
crepant cases, both IHC versus FISH scores and  inter-reader 
scores were discussed among the readers, and after this dis-
cussion four readers made a total of eight changes. Each of the 
four readers changed one IHC-positive case to IHC negative 
and two readers each changed two unevaluable cases to IHC 
negative. Among the cases that were changed from positive 
to negative, one was changed because of macrophage stain-
ing, two because of weak staining, and one because it was a 
score-sheet entry input error. Among the unevaluable to nega-
tive cases three were related to number of tumor cells in the 
specimens and one case was a score-sheet entry input error. 
These changes are detailed in Table 2, which shows that there 
was no change in overall sensitivity, accuracy changed by less 
than 1%, and specificity changed from 95% to 96% after the 
review of the discrepant cases. To determine whether having 
a majority score improved upon the results of the individual 
readers, the cases were then classified as either positive or 
negative based on four of the seven readers agreeing upon the 
score before consensus review. Table 3 shows that results of 
this majority score were minimally different than that of any 
of the individual readers, with the biggest difference being 
relative to reader 5 who had a sensitivity of 87% (39 IHC+/45 
FISH+), whereas the majority score sensitivity was 91% (39 
IHC+/43 FISH+). Taken together these data indicate that the 
FIGURE 1.  Anaplastic lymphoma 
kinase immunohistochemistry stain-
ing. A–C, Examples of positive stain-
ing. D, Example of negative staining. 
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ALK IHC test is sensitive, specific, and accurate relative to 
FISH and that having a majority score of multiple readers 
does not improve these parameters over an individual reader.
Agreement between Readers for 
ALK Protein Expression
The agreement between the IHC scores for each of the 
readers was then evaluated for the 100 ALK IHC evaluable 
cases. Table 4 shows that all seven readers agreed on 48 ALK 
IHC-negative cases and 40 ALK IHC-positive cases, there-
fore, there was a striking 100% agreement among all seven 
readers on 88% of the total cases. Interestingly, three of the 48 
cases with 100% agreement on IHC negativity were classified 
as ALK FISH-positive and two of the 40 IHC-positive cases 
with 100% reader agreement were deemed FISH negative. Six 
of seven readers (86%) agreed on seven IHC-negative cases 
and one IHC positive case. The FISH status of these cases is 
shown in Table 4 as well as the score from the reader that did 
TABLE 2.   ALK IHC vs. ALK FISH for All Readers and Overall after Consensus Review
Reader
(n evaluable) IHC FISH + FISH− Sensitivity (95% CI) Specificity (95% CI) Accuracy (95% CI)
Reader 1 (n = 97) IHC+ 39 2
91 (78–96) 96 (88–99) 94 (87–97)
IHC− 4 52
Reader 2 (n = 99) IHC+ 39 2
89 (76–95) 96 (88–99) 93 (86–97)
IHC− 5 53
Reader 3 (n = 99) IHC+ 39 2
89 (76–95) 96 (88–99) 93 (86–97)
IHC− 5 53
Reader 4 (n = 99) IHC+ 42 2*
93 (82–98) 96* (88–99) 95* (89–98)
IHC− 3 52*
Reader 5 (n = 99) IHC+ 39 2*
87 (74–94) 96* (88–99) 92* (85–96)
IHC− 6 52*
Reader 6 (n = 99)* IHC+ 40 2*
91 (79–96) 96* (88–99) 94* (87–97)
IHC− 4 53*
Reader 7 (n = 99)* IHC+ 40 2*
91 (79–96) 96* (88–99) 94* (87–97)
IHC− 4 53*
Overall (n = 691)* IHC+ 278 14*
90 (80–98) 96* (90–100) 93* (88–98)IHC − 31 368*
ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, fluoroscence in situ hybridization; CI, confidence interval.
*indicates changes from Table 1.
TABLE 1.  ALK IHC vs. ALK FISH for All Readers and Overall
Reader
(n Evaluable) FISH+ FISH− Sensitivity (95% CI) Specificity (95% CI) Accuracy (95% CI)
Reader 1 (n = 97) IHC+ 39 2
91 (78–96) 96 (88–99) 94 (87–97)
IHC− 4 52
Reader 2 (n = 99) IHC+ 39 2
89 (76–95) 96 (88–99) 93 (86–97)
IHC− 5 53
Reader 3 (n = 99) IHC+ 39 2
89 (76–95) 96 (88–99) 93 (86–97)
IHC− 5 53
Reader 4 (n = 99) IHC+ 42 3
93 (82–98) 94 (85–99) 94 (87–97)
IHC− 3 51
Reader 5 (n = 99) IHC+ 39 3
87 (74–94) 94 (85–98) 91 (84–95)
IHC− 6 51
Reader 6 (n = 97) IHC+ 40 3
91 (79–96) 94 (85–98) 93 (86–97)
IHC− 4 50
Reader 7 (n = 97) IHC+ 40 3
91 (79–96) 94 (85–98) 93 (86–97)
IHC− 4 50
Overall (n = 687) IHC+ 278 18
90 (80–98) 95 (89–99) 93 (88–97)IHC− 31 360
ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, fluoroscence in situ hybridization; CI, confidence interval.
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not align with the other six readers. For the remaining four 
cases there was agreement between five of seven and four of 
seven readers for one IHC-negative cases each and three of 
seven readers agreement for two IHC-positive cases. The FISH 
status and other readers’ scores on these cases can be seen in 
Table 4. Table 5 shows that after the consensus review of the 
few discrepant cases there was 100% agreement between the 
seven readers on 95% of the total cases; 55 IHC-negative cases 
and 30 IHC-positive cases. There were still three cases with 
seven of seven agreement on IHC negative but FISH positive 
and two cases with seven of seven agreement on IHC posi-
tive but FISH negative. There were two cases with only six of 
seven agreement, one case with four of seven agreement, and 
two cases with three of seven agreement; the FISH status of 
the cases as well as the nonmajority readers’ scores are listed 
in Table 5. As a whole there was extremely close agreement 
between all seven expert readers for a majority of the cases.
Assay Background
To evaluate the possibility that the detection system 
used with this ALK IHC kit, which uses an amplification step, 
produces some nonspecific background (e.g., nontumor cell 
or acellular staining) that would hinder the accurate scoring 
of specimens, six of the seven expert readers assessed staining 
in the nontumor regions of the specimens. Table 6 shows that 
high background ranged from 0% to 23% of the cases, with 
the average being 11% of the cases. Although the readers did 
report some high background, this did not seem to have a neg-
ative impact on the overall ability of the readers to accurately 
score the specimens, as shown by the overall 90% sensitiv-
ity, 95% specificity, and 93% accuracy relative to FISH status 
(Tables 1 and 2). Likewise, the background did not seem to 
negatively influence the inter-reader scores, as shown by the 
high concordance between the readers (Tables 4 and 5) and the 
97% agreement (95 of 98 cases) between readers 3 and 4, who 
reported the widest range of background levels, 0% to 23% of 
the cases, respectively.
DISCUSSION
The goal of this study was to bring together for the first 
time an international team of experts to evaluate a new stan-
dardized ALK IHC assay with automated staining. On the 
basis of the evaluation of 100 cases by ALK IHC and com-
pared with prior ALK FISH results it was observed that the 
IHC test is sensitive, specific, and accurate compared with 
FISH and that having a majority score of multiple readers does 
not improve these results over an individual reader’s score. 
Even after having a consensus review the sensitivity stayed 
the same and specificity and accuracy were only marginally 
improved, indicative of consistency and accuracy with the 
assay and readers before the consensus review. To achieve a 
high-quality standardized assay there needs to be high inter-
reader agreement among readers, and this study demonstrated 
extremely close agreement with 100% agreement among seven 
readers on 88% of the total cases and only four cases (4%) 
with a reader agreement of five of seven or lesser. After the 
consensus review there was 100% agreement among the seven 
readers on 95% of the cases and there were three cases with a 
reader agreement of five of seven or lesser. Thus the shift was 
because of changes from the six of seven agreement to seven 
of seven agreement. These three cases were all surgical resec-
tions where one case had preservation issues and two cases had 
few tumor cells remaining. There were few cases with hetero-
geneous staining. There were two cases where the differences 
in staining we observed seemes to be because of variations 
in protein expression within the specimens (Fig. 2), similar 
to what we have observed in the two NSCLC  ALK-positive 
cell lines H2228 and H3122 where some cells within the block 
TABLE 3.  ALK IHC vs. ALK FISH for Majority Score, Four of Seven Readers in Agreement
Reader
(n evaluable) IHC FISH+ FISH− Sensitivity (95% CI) Specificity (95% CI) Accuracy (95% CI)
Four-reader agreement IHC+ 39 2
91 (78–96) 96 (88–99) 94 (87–97)IHC− 4 53
ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, fluoroscence in situ hybridization; CI, confidence interval.
TABLE 4.   ALK IHC Reader Agreement before Consensus Review
Number of  
Cases by IHC Readers Agree FISH Status Other Readers Score FISH Status Other Readers Score
48 IHC Neg 7/7 45 FISH Neg 3 FISH Pos
40 IHC Pos 7/7 2 FISH Neg 38 FISH Pos
7 IHC Neg 6/7 6 FISH Neg 4 IHC Pos, 2 Uneval 1 FISH Pos 1 IHC Pos
1 IHC Pos 6/7 1 FISH Pos 1 IHC Neg
1 IHC Neg 5/7 1 FISH Neg 2 Uneval
1 IHC Neg 4/7 1 FISH Neg 1 IHC Pos, 2 Uneval
1 IHC Pos 3/7 1 FISH Pos 3 IHC Neg, 1 Uneval
1 IHC Pos 3/7 1 FISH Pos 4 Uneval
ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, fluoroscence in situ hybridization, Neg, negative; Pos, positive; Uneval, unevaulable. 
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have very high expression whereas others have more modest 
expression (Wynes and Hirsch, unpublished data, 2013). We 
detected another two cases where there may have been some 
differences in staining intensity because of fixation issues in 
the center of the specimen; however, we had no cases that dis-
played definitive positive staining in one area and negative in 
other tumor areas. Heterogeneity was not a source of discrep-
ancy among the readers; likewise, there were no discrepancies 
between these cases and FISH as all were scored positive by 
IHC as well as FISH. Although some readers did report some 
background (0%–23% of the cases) depending on reader, this 
did not affect the sensitivity, specificity, or accuracy relative to 
FISH or the inter-reader agreement, therefore this seems to be 
a quality standardized ALK IHC test.
There have been some significant treatment advances 
for patients with advanced NSCLC in the past few years, 
which have led to increased PFS and quality of life. These 
improvements have come through a better understanding that 
lung cancers are driven by genetic abnormalities and that 
these genetic abnormalities can be targeted therapeutically.4–10 
ALK inhibitors, like crizotinib, but many others in the pipe-
line, are highly effective in patients that have ALK rearrange-
ment. But to treat these patients there needs to be a validated 
companion diagnostic that accurately identifies these patients. 
The only FDA-approved companion diagnostic for ALK 
inhibitor selection is the Abbott break-apart FISH assay.21 
Unfortunately, this assay only indicates whether the ALK gene 
is broken at the DNA level and does not determine whether 
there has been a productive rejoining of the DNA creating a 
continuous open reading frame that results in a complete chi-
meric mRNA transcript and ultimately a translated functional 
fusion protein. It may be assumed that an ALK rearrangement 
detected by FISH always leads to a productive transcript and 
protein expression. However, it is entirely possible that after a 
chromosomal rearrangement a stop codon may be generated 
at the break point or that a 5′ fusion partner without promoter 
activity or that no fusion partner at all is rejoined to 3′ ALK, all 
of which would give a FISH break-apart signal but not a pro-
ductive transcript and functional protein. This may explain the 
observation that there are some FISH-positive patients who 
do not receive clinical benefit from crizotinib, for example, 25 
of 143 evaluable patients (17.5%), who were all FISH posi-
tive, in the international phase I never achieved disease con-
trol.9 Conversely, there are FISH-negative, but IHC-positive, 
patients who actually do receive significant clinical benefit 
from crizotinib.29,30 However, these latter examples are lim-
ited case reports because all the clinical trials to date required 
positivity by FISH to be included in a study.
A potentially better assay to select patients to receive an 
ALK inhibitor is one that detects ALK expression at the pro-
tein level. This assay would then allow one to verify that the 
actual protein target of the inhibitor, that is, the ATP-binding 
pocket in the kinase domain of ALK, is present, alleviate any 
concern about unproductive ligation after rearrangement, and 
detect any expression mediated by any other aberrant nonrear-
rangement mechanism. ALK is not normally expressed in the 
lung and any expression would be considered abnormal.
IHC is an assay that would meet all these requirements 
and it has been in the routine clinical setting for decades, 
is cost effective, and does not demand unusual expertise to 
evaluate the specimen. Many studies have shown strong cor-
relations between ALK IHC and FISH, and in an early study 
comparing ALK IHC with ALK FISH in 153 lung adenocarci-
noma (ADC) patients it was shown that there was a difference 
in sensitivity and specificity relative to FISH, depending on 
the clone of antibody used with the D5F3 clone generating 
a sensitivity and specificity of 100% and 99%, respectively, 
whereas that of the ALK1 antibody was only 67% and 97%, 
respectively.24 The method of detection here was the Dako 
EnVision+ system (Dako North America, Inc., Carpinteria, 
CA). In a study with a large series of 640 patients (450 ADC, 
163 squamous cell carcinoma [SCC], 27 other histologies) 
and using the 5A4 clone with the iView detection system 
(Ventana) the authors observed a sensitivity of 100% and a 
specificity of 98% with 10 of 640 patients displaying FISH 
TABLE 6.  ALK IHC Cases with High Background
Reader n/N (%)
1 4/99 (4.0)
2 N/A
3 0/98 (0)
4 23/99 (23.2)
5 9/99 (9.1)
6 9/97 (9.3)
7 19/97 (19.6)
ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; N/A, not available. 
TABLE 5.  ALK IHC Reader Agreement after Consensus Review
Number of  
Cases by IHC Readers Agree FISH Status Other Readers Score FISH Status Other Readers Score
55 IHC Neg 7/7 52 FISH Neg 3 FISH Pos
40 IHC Pos 7/7 2 FISH Neg 38 FISH Pos
1 IHC Neg 6/7 1 FISH Pos 1 IHC Pos
1 IHC Pos 6/7 1 FISH Pos 1 IHC Neg
1 IHC Neg 4/7 1 FISH Neg 1 IHC Pos, 2 Uneval
1 IHC Pos 3/7 1 FISH Pos 3 IHC Neg, 1 Uneval
1 IHC Pos 3/7 1 FISH Pos 4 Uneval
ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, fluoroscence in situ hybridization, Neg, negative; Pos, positive; Uneval, unevaulable. 
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negativity but IHC positivity.25 A 90% sensitivity and 98% 
specificity was found when comparing IHC with FISH in a 
small series of 101 ADC patients using the ALK1 clone and 
the Dako ADVANCE detection system (Dako North America, 
Inc.).33 A more recent study by To et al,26 examined 373 ADC 
patients by ALK IHC and 351 of those by ALK FISH. They 
found 22 IHC-positive cases of which 20 were FISH positive, 
giving rise to a sensitivity of 100% and specificity of 99%, 
however, when the 22 IHC-positive cases were subjected to 
reverse transcription-polymerase chain reaction (RT-PCR) the 
two IHC-positive/FISH-negative cases were, in fact, positive 
by RT-PCR, suggesting FISH false negativity. This study used 
the clone 5A4 (Abcam, Cambridge, United Kingdom) and the 
polymer refined detention kit (Leica Microsystems, GmbH, 
Germany). In a comprehensive study of 377 cases (145 ADCs, 
178 SCCs, and 54 other histologies) three antibody clones 
(5A4, ALK1, and D5F3) were combined with three detection 
systems, with the two best combinations showing 100% sensi-
tivity, 88% specificity using 5A4 with ADVANCE and 100% 
sensitivity and 75% specificity using D5F3 with ADVANCE.23 
In a report examining only cytology specimens Savic et al.34 
reported a 93% sensitivity and 96% sensitivity when com-
paring immunocytochemistry with FISH and using the 5A4 
antibody clone. Interestingly, immunocytochemistry identi-
fied two cases as ALK positive, which were originally clas-
sified as FISH negative, however, on reanalysis of the FISH 
these two cases were determined to be in fact FISH positive. 
Finally, in a study where the D5F3 antibody was used with the 
OptiView DAB detection and OptiView amplification system, 
the same as used in our study, they observed 94% sensitiv-
ity (31 IHC+/33 FISH+) and 100% specificity (198 IHC−/198 
FISH−) when comparing IHC with FISH formalin-fixed, 
paraffin-embedded tissue. However, the two discrepant cases 
were subsequently reclassified as FISH negative on ThinPrep 
specimens from the same patients, thus increasing the sensi-
tivity to 100%.27 Collectively all these studies convey the same 
message, IHC correlates well with FISH with a very few cases 
showing discrepancy, but the biggest limitation is that the anti-
body clones, antigen retrieval, detection systems, and scoring 
methodology were not standardized.
In the cohort presented in our study there were three 
FISH-positive cases that were scored IHC negative by seven 
of seven readers, two FISH-negative cases scored IHC posi-
tive by seven of seven readers, and one FISH-positive case 
scored IHC negative by six of seven readers. The best way 
to resolve this conflict from an assay detection perspective 
would be to perform a third assay that would preferably detect 
more than just a break-apart gene. One such assay would be 
 next-generation sequencing on the genomic DNA, which could 
detect break-points, an open reading frame, and any poten-
tial novel 5′ fusion partner, but would not detect expression. 
Another approach using RT-PCR combined with sequencing 
could detect break-apart, if the 5′ partner is known, and verify 
expression at the mRNA level. Unfortunately there was not 
enough material to perform any additional assays to further 
resolve the few discrepancies observed between IHC and 
FISH in our study.
In the future the only way to fully understand and 
appreciate how well IHC compares with FISH in predicting 
response and outcome to ALK inhibitors is to have well-
designed prospective clinical trials that evaluate the effi-
cacy of ALK inhibitors in IHC+/ FISH− or IHC−/FISH+ 
patients. The most favorable IHC assay for this screening 
should be one that has been thoroughly standardized and 
has exquisitely sensitive detection/amplification systems 
with limited background to consistently identify all levels 
of ALK protein expression.
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